Results 271 to 280 of about 157,884 (362)
Clinical Validation of Plasma p‐217tau in Neurological Diseases
ABSTRACT Objective Plasma p‐217tau is a minimally invasive but specific biomarker for diagnosing Alzheimer's disease (AD). However, its disease specificity remains to be clinically evaluated. We validated the reliability of the p‐217tau biomarker in 12 other neurological diseases.
Takeshi Kawarabayashi +13 more
wiley +1 more source
Parametric Optimization of VLM Panel Discretization Using Bio-Inspired Crayfish and Aquila Algorithms Coupled with Hybrid RSM-Based Ensemble Machine Learning Surrogate Models: A Case Study. [PDF]
Eraslan Y, Şengün E.
europepmc +1 more source
ANALYSIS OF THE AERODYNAMIC CHARACTERISTICS OF AN AIRSHIP AT HIGH ANGLES OF ATTACK
Chen Feilong +2 more
openalex +1 more source
ABSTRACT The Clinical Assessment Scale in Autoimmune Encephalitis (CASE) tracks disease severity in autoimmune encephalitis (AE), but no threshold for significant change exists. We aimed to determine the minimally clinically important difference (MCID) for CASE.
Yihui Goh +8 more
wiley +1 more source
Dynamic Analysis of Bi-Stable Galloping Energy Harvesters Under Random Excitation. [PDF]
Zhang Y, Qin R, Zheng K, Zhang J.
europepmc +1 more source
Von Economo Neuron Loss in Frontotemporal Dementia: A Meta‐Analysis of Neuropathological Studies
ABSTRACT Von Economo neurons (VENs) have been reported to be vulnerable to neurodegeneration in frontotemporal dementia (FTD), particularly the behavioral variant (bvFTD), but these findings have not been systematically assessed across independent brain banks.
Daniel Talmasov +2 more
wiley +1 more source
Wavy collector design for high-efficiency solar chimney power plants. [PDF]
Elsayed AM, Aziz MA, Elshimy H.
europepmc +1 more source
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants
Multiple Sclerosis Relapse Activity After Ozanimod Discontinuation in DAYBREAK Trial Participants. ABSTRACT Objective Return of disease activity is expected when patients discontinue disease‐modifying therapy (DMT) for multiple sclerosis (MS). Some MS DMTs are associated with higher‐than‐expected disease activity (rebound) after discontinuation.
Ralf Gold +12 more
wiley +1 more source

